NOVOZYMES A/S SPONS.ADR 1 (NZM) — Cash Flow Quality Index
NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Cash Flow Quality Index of 0.84x as of March 2026. Operating cash flow of €167.10 Million is below net income of €199.10 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore balance sheet size of NOVOZYMES A/S SPONS.ADR 1 for the complete picture of this company's asset base.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
NOVOZYMES A/S SPONS.ADR 1 Cash Flow Quality Index (2021–2025)
Historical Cash Flow Quality Index for NOVOZYMES A/S SPONS.ADR 1 across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check NOVOZYMES A/S SPONS.ADR 1 tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Year-by-year earnings quality comparison for NOVOZYMES A/S SPONS.ADR 1. For live market cap and the full company financial profile, see NOVOZYMES A/S SPONS.ADR 1 stock valuation.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.09x | €1.22 Billion | €583.60 Million | ▲ +368.1% |
| 2024 | 0.45x | €1.02 Billion | €2.28 Billion | ▲ +142.7% |
| 2023 | 0.18x | €557.10 Million | €3.02 Billion | ▲ +26.0% |
| 2022 | 0.15x | €537.65 Million | €3.68 Billion | ▼ -88.7% |
| 2021 | 1.29x | €546.17 Million | €423.00 Million | — |